Xencor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Xencor and other ETFs, options, and stocks.

About XNCR

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. 

CEO
Bassil I. Dahiyat
CEOBassil I. Dahiyat
Employees
260
Employees260
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1997
Founded1997
Employees
260
Employees260

XNCR Key Statistics

Market cap
891.06M
Market cap891.06M
Price-Earnings ratio
-9.55
Price-Earnings ratio-9.55
Dividend yield
Dividend yield
Average volume
928.93K
Average volume928.93K
High today
$12.27
High today$12.27
Low today
$11.62
Low today$11.62
Open price
$11.62
Open price$11.62
Volume
235.18K
Volume235.18K
52 Week high
$18.69
52 Week high$18.69
52 Week low
$6.92
52 Week low$6.92

Stock Snapshot

With a market cap of 891.06M, Xencor(XNCR) trades at $12.15. The stock has a price-to-earnings ratio of -9.55.

During the trading session on 2026-03-10, Xencor(XNCR) shares reached a daily high of $12.27 and a low of $11.62. At a current price of $12.15, the stock is +4.6% higher than the low and still -1.0% under the high.

Trading volume for Xencor(XNCR) stock has reached 235.18K, versus its average volume of 928.93K.

Over the past 52 weeks, Xencor(XNCR) stock has traded between a high of $18.69 and a low of $6.92.

Over the past 52 weeks, Xencor(XNCR) stock has traded between a high of $18.69 and a low of $6.92.

XNCR News

TipRanks 14h
Xencor Insider Shake-Up: Top Executives Quietly Cash Out Shares

New insider activity at Xencor ( (XNCR) ) has taken place on March 9, 2026. Several top executives at Xencor have recently sold notable amounts of company stoc...

TipRanks 19h
Xencor, Genentech to End Protein Therapeutics Collaboration

Xencor ( (XNCR) ) just unveiled an update. Xencor, Inc., a biopharmaceutical developer of engineered protein therapeutics, has relied on collaborations with ma...

TipRanks 20h
Xencor reports receipt of notice of termination of license agreement from Roche

In a regulatory filing, Xencor (XNCR) disclosed that on March 4, the company received a notice of termination of an Amended and Restated Collaboration and Licen...

Analyst ratings

92%

of 13 ratings
Buy
92.3%
Hold
7.7%
Sell
0%

More XNCR News

Benzinga 5d
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor

On Wednesday, Xencor Inc. (NASDAQ:XNCR) said it is revising its revenue outlook for royalties tied to Ultomiris. The company announced that its licensee, Alexi...

Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
TipRanks 6d
Xencor expects cash to fund operations into mid-2028

Xenco announced that Alexion Pharmaceuticals informed Xencor (XNCR) that it has taken the position that the Licensee does not owe any additional royalties for s...

People also own

Based on the portfolios of people who own XNCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.